Randomized cooperative study of perioperative chemotherapy in breast cancer

M. R. Sertoli, P. Bruzzi, P. Pronzato, P. Queirolo, D. Amoroso, L. Del Mastro, M. Venturini, A. Vigani, G. Bertelli, E. Campora, F. Boccardo, C. Monzeglio, E. Paganini, G. Pastorino, G. Canavese, A. Catturich, F. Cafiero, C. Vecchio, P. Miccoli, A. RubagottiR. Rosso

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: The aim of this multicentric randomized trial was to determine whether reducing the interval between surgery and chemotherapy improves the outcome of breast cancer patients. Patients and Methods: Between June 1985 and July 1992, 600 breast cancer patients, clinical stages T1-3A,NO-2,MO were randomly assigned to a perioperative cycle (PC) of cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF). Node- negative (N-) patients did not receive any further treatment. Node positive (N+) patients received 11 cycles if previously given PC, or 12 cycles of CEF alternated with cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 (CMF). In addition, N+ patients received concomitant or sequential 5-year tamoxifen therapy. Results: At a median follow-up duration of 5.7 years, no significant difference in survival (88% v 84%, P = .3) between the two treatment arms was seen. However, a difference of borderline significance in relapse-free survival (RFS; 76% v 70%, P = .053) was evident. A significant survival advantage for the PC arm was detected only in the estrogen receptor-negative (ER) patients (P = .003). RFS was significantly improved in N- patients, postmenopausal patients, and ER- patients. Multivariate analyses show that pathologic tumor size, nodal status, receptor status, and treatment (only in ER- patients) are significantly correlated with survival and RFS. PC toxicity did not influence wound healing. Conclusion: This study provides preliminary evidence that PC positively affects relapse rate and survival in some subgroups, namely, ER- patients.

Original languageEnglish
Pages (from-to)2712-2721
Number of pages10
JournalJournal of Clinical Oncology
Volume13
Issue number11
Publication statusPublished - Nov 1995

Fingerprint

Breast Neoplasms
Drug Therapy
Estrogen Receptors
Survival
Fluorouracil
Cyclophosphamide
Recurrence
Tamoxifen
Therapeutics
Methotrexate
Wound Healing
Multivariate Analysis
Survival Rate
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized cooperative study of perioperative chemotherapy in breast cancer. / Sertoli, M. R.; Bruzzi, P.; Pronzato, P.; Queirolo, P.; Amoroso, D.; Del Mastro, L.; Venturini, M.; Vigani, A.; Bertelli, G.; Campora, E.; Boccardo, F.; Monzeglio, C.; Paganini, E.; Pastorino, G.; Canavese, G.; Catturich, A.; Cafiero, F.; Vecchio, C.; Miccoli, P.; Rubagotti, A.; Rosso, R.

In: Journal of Clinical Oncology, Vol. 13, No. 11, 11.1995, p. 2712-2721.

Research output: Contribution to journalArticle

Sertoli, MR, Bruzzi, P, Pronzato, P, Queirolo, P, Amoroso, D, Del Mastro, L, Venturini, M, Vigani, A, Bertelli, G, Campora, E, Boccardo, F, Monzeglio, C, Paganini, E, Pastorino, G, Canavese, G, Catturich, A, Cafiero, F, Vecchio, C, Miccoli, P, Rubagotti, A & Rosso, R 1995, 'Randomized cooperative study of perioperative chemotherapy in breast cancer', Journal of Clinical Oncology, vol. 13, no. 11, pp. 2712-2721.
Sertoli, M. R. ; Bruzzi, P. ; Pronzato, P. ; Queirolo, P. ; Amoroso, D. ; Del Mastro, L. ; Venturini, M. ; Vigani, A. ; Bertelli, G. ; Campora, E. ; Boccardo, F. ; Monzeglio, C. ; Paganini, E. ; Pastorino, G. ; Canavese, G. ; Catturich, A. ; Cafiero, F. ; Vecchio, C. ; Miccoli, P. ; Rubagotti, A. ; Rosso, R. / Randomized cooperative study of perioperative chemotherapy in breast cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 11. pp. 2712-2721.
@article{9cb445f26c544aa09d7855176a1ac8ee,
title = "Randomized cooperative study of perioperative chemotherapy in breast cancer",
abstract = "Purpose: The aim of this multicentric randomized trial was to determine whether reducing the interval between surgery and chemotherapy improves the outcome of breast cancer patients. Patients and Methods: Between June 1985 and July 1992, 600 breast cancer patients, clinical stages T1-3A,NO-2,MO were randomly assigned to a perioperative cycle (PC) of cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF). Node- negative (N-) patients did not receive any further treatment. Node positive (N+) patients received 11 cycles if previously given PC, or 12 cycles of CEF alternated with cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 (CMF). In addition, N+ patients received concomitant or sequential 5-year tamoxifen therapy. Results: At a median follow-up duration of 5.7 years, no significant difference in survival (88{\%} v 84{\%}, P = .3) between the two treatment arms was seen. However, a difference of borderline significance in relapse-free survival (RFS; 76{\%} v 70{\%}, P = .053) was evident. A significant survival advantage for the PC arm was detected only in the estrogen receptor-negative (ER) patients (P = .003). RFS was significantly improved in N- patients, postmenopausal patients, and ER- patients. Multivariate analyses show that pathologic tumor size, nodal status, receptor status, and treatment (only in ER- patients) are significantly correlated with survival and RFS. PC toxicity did not influence wound healing. Conclusion: This study provides preliminary evidence that PC positively affects relapse rate and survival in some subgroups, namely, ER- patients.",
author = "Sertoli, {M. R.} and P. Bruzzi and P. Pronzato and P. Queirolo and D. Amoroso and {Del Mastro}, L. and M. Venturini and A. Vigani and G. Bertelli and E. Campora and F. Boccardo and C. Monzeglio and E. Paganini and G. Pastorino and G. Canavese and A. Catturich and F. Cafiero and C. Vecchio and P. Miccoli and A. Rubagotti and R. Rosso",
year = "1995",
month = "11",
language = "English",
volume = "13",
pages = "2712--2721",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Randomized cooperative study of perioperative chemotherapy in breast cancer

AU - Sertoli, M. R.

AU - Bruzzi, P.

AU - Pronzato, P.

AU - Queirolo, P.

AU - Amoroso, D.

AU - Del Mastro, L.

AU - Venturini, M.

AU - Vigani, A.

AU - Bertelli, G.

AU - Campora, E.

AU - Boccardo, F.

AU - Monzeglio, C.

AU - Paganini, E.

AU - Pastorino, G.

AU - Canavese, G.

AU - Catturich, A.

AU - Cafiero, F.

AU - Vecchio, C.

AU - Miccoli, P.

AU - Rubagotti, A.

AU - Rosso, R.

PY - 1995/11

Y1 - 1995/11

N2 - Purpose: The aim of this multicentric randomized trial was to determine whether reducing the interval between surgery and chemotherapy improves the outcome of breast cancer patients. Patients and Methods: Between June 1985 and July 1992, 600 breast cancer patients, clinical stages T1-3A,NO-2,MO were randomly assigned to a perioperative cycle (PC) of cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF). Node- negative (N-) patients did not receive any further treatment. Node positive (N+) patients received 11 cycles if previously given PC, or 12 cycles of CEF alternated with cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 (CMF). In addition, N+ patients received concomitant or sequential 5-year tamoxifen therapy. Results: At a median follow-up duration of 5.7 years, no significant difference in survival (88% v 84%, P = .3) between the two treatment arms was seen. However, a difference of borderline significance in relapse-free survival (RFS; 76% v 70%, P = .053) was evident. A significant survival advantage for the PC arm was detected only in the estrogen receptor-negative (ER) patients (P = .003). RFS was significantly improved in N- patients, postmenopausal patients, and ER- patients. Multivariate analyses show that pathologic tumor size, nodal status, receptor status, and treatment (only in ER- patients) are significantly correlated with survival and RFS. PC toxicity did not influence wound healing. Conclusion: This study provides preliminary evidence that PC positively affects relapse rate and survival in some subgroups, namely, ER- patients.

AB - Purpose: The aim of this multicentric randomized trial was to determine whether reducing the interval between surgery and chemotherapy improves the outcome of breast cancer patients. Patients and Methods: Between June 1985 and July 1992, 600 breast cancer patients, clinical stages T1-3A,NO-2,MO were randomly assigned to a perioperative cycle (PC) of cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF). Node- negative (N-) patients did not receive any further treatment. Node positive (N+) patients received 11 cycles if previously given PC, or 12 cycles of CEF alternated with cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 (CMF). In addition, N+ patients received concomitant or sequential 5-year tamoxifen therapy. Results: At a median follow-up duration of 5.7 years, no significant difference in survival (88% v 84%, P = .3) between the two treatment arms was seen. However, a difference of borderline significance in relapse-free survival (RFS; 76% v 70%, P = .053) was evident. A significant survival advantage for the PC arm was detected only in the estrogen receptor-negative (ER) patients (P = .003). RFS was significantly improved in N- patients, postmenopausal patients, and ER- patients. Multivariate analyses show that pathologic tumor size, nodal status, receptor status, and treatment (only in ER- patients) are significantly correlated with survival and RFS. PC toxicity did not influence wound healing. Conclusion: This study provides preliminary evidence that PC positively affects relapse rate and survival in some subgroups, namely, ER- patients.

UR - http://www.scopus.com/inward/record.url?scp=0028842792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028842792&partnerID=8YFLogxK

M3 - Article

C2 - 7595729

AN - SCOPUS:0028842792

VL - 13

SP - 2712

EP - 2721

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -